Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Shutdown Lands Hard On CFSAN-Regulated Industries

This article was originally published in The Tan Sheet

Executive Summary

The federal shutdown interrupts FDA’s increasing enforcement against firms marketing violative supplement products in addition to slowing drug application evaluations and facility inspections. FDA would retain 8,180 staff members, about 55% of its total, mostly because they could be “paid from carryover funding.”

You may also be interested in...



Sequester, Shutdown Hurt FDA Recruitment, Morale – Hamburg

The FDA commissioner tells a House subcommittee that a job candidate questioned whether the “uncertainty” of government work was worth leaving academia, reflecting sentiment that challenges the agency’s efforts to fill senior leadership positions.

Sequester, Shutdown Hurt FDA Recruitment, Morale – Hamburg

The FDA commissioner tells a House subcommittee that a job candidate questioned whether the “uncertainty” of government work was worth leaving academia, creating another hurdle for agency efforts to fill senior leadership positions.

Sequester, Shutdown Hurt FDA Recruitment, Morale – Hamburg

The FDA commissioner tells a House subcommittee that a job candidate questioned whether the “uncertainty” of government work was worth leaving academia, creating another hurdle for agency efforts to fill senior leadership positions.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS106645

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel